The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials

被引:27
|
作者
Wang, Wuwan [1 ]
Hu, Xiankang [2 ]
Liao, Weitin [2 ]
Rutahoile, W. H. [1 ]
Malenka, David [3 ]
Zeng, Xiaofang [1 ]
Yang, Yunjing [1 ]
Feng, Panpan [1 ]
Wen, Li [1 ]
Huang, Wei [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China
[2] Chongqing Med Univ, Chongqing, Peoples R China
[3] Dartmouth Hitchcock Med Ctr, Sect Cardiovasc Med, Lebanon, NH 03766 USA
基金
中国国家自然科学基金;
关键词
Fontan procedure; PDE-5; inhibitor; endothelin-1 receptor antagonist; outcomes; EXERCISE CAPACITY; DOUBLE-BLIND; NITRIC-OXIDE; SILDENAFIL; BOSENTAN; ADULTS; OPERATION; IMPACT; HEMODYNAMICS; ADOLESCENTS;
D O I
10.1177/2045894018790450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = -0.39, 95% CI: [-0.72, -0.05]) in the New York Heart Association (NYHA) functional class. The 6-minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO2 was also significantly improved (mean difference = 1.42 ml center dot(kg center dot min)(-1), 95% CI: [0.21, 2.63]). Additionally, the mean pulmonary artery pressure (mPAP) was significantly reduced (mean difference = -2.25 mmHg, 95% CI: [-3.00, -1.50]). No significant change was found in mortality or in brain natriuretic peptide (BNP) or N-terminal pronatriuretic peptide (NT-proBNP). Four studies reported no side effects and good drug tolerance, and two studies reported mild adverse effects. The present meta-analysis indicated that pulmonary vasodilators (primarily the PDE-5 inhibitor and endothelin-1 receptor antagonist) significantly improved the hemodynamics of Fontan patients, reduced the NYHA functional class and increased the 6MWD. The peak oxygen consumption was also improved. No significant change was observed in mortality or in the BNP or NT-proBNP level. Overall, the pulmonary vasodilators were well tolerated. This finding needs to be confirmed in future studies.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The Efficacy and Safety of Pulmonary Vasodilators in Patients With Fontan Circulation: A Meta-Analysis of Randomized-Controlled Trials
    Wang, Wuwan
    Huang, Wei
    Liao, Weiting
    Hu, Kang
    Rutahoile, W. H.
    Zeng, Xiaofang
    Yang, Yunjing
    [J]. CIRCULATION, 2017, 136
  • [2] Efficacy and Safety of Pulmonary Vasodilators in the Patients With Eisenmenger Syndrome: A Meta-Analysis of Randomized Controlled Trials
    Hou, Yulin
    Huang, Wei
    [J]. CIRCULATION, 2019, 140
  • [3] Efficacy and safety of pulmonary vasodilators in the patients with Eisenmenger syndrome: a meta-analysis of randomized controlled trials
    Hou, Yulin
    Wen, Li
    Shu, Tingting
    Dai, Rong
    Huang, Wei
    [J]. PULMONARY CIRCULATION, 2021, 11 (02)
  • [4] Pulmonary vasodilators and exercise in Fontan circulation: a systematic review and meta-analysis
    Kosmidis, Diamantis
    Arvanitaki, Alexandra
    Farmakis, Ioannis T.
    Liakos, Aris
    Giannopoulos, Andreas
    Ziakas, Antonios
    Giannakoulas, George
    [J]. HEART, 2024, 110 (08) : 552 - 559
  • [5] Efficacy and safety of thrombolytic therapy in pulmonary embolism: meta-analysis of randomized controlled trials
    Serra-Prat, M
    Jovell, AJ
    Aymerich, M
    [J]. MEDICINA CLINICA, 1999, 112 (18): : 685 - 689
  • [6] Efficacy and safety of thrombolytic therapy in pulmonary embolism:: meta-analysis of randomized controlled trials
    Tejero, ES
    Gámez, BJ
    Amieva, AG
    García, ES
    [J]. MEDICINA CLINICA, 1999, 113 (18): : 717 - 717
  • [7] The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials
    Li, Benlei
    Fang, Dong
    Qian, Cheng
    Feng, Hongliang
    Wang, Yanggan
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (04) : 327 - 342
  • [8] Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials
    Liu, Jun-Ying
    Guo, Li-Na
    Peng, Wan-Zhong
    Jiang, Yang
    Wang, Ai-Li
    Guo, Xue-Min
    Xu, Ze-Sheng
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (10)
  • [9] The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials
    Benlei Li
    Dong Fang
    Cheng Qian
    Hongliang Feng
    Yanggan Wang
    [J]. Clinical Drug Investigation, 2017, 37 : 327 - 342
  • [10] The efficacy and safety of sulodexide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials
    Shang, Hong-Xia
    Zhao, Jun-Yu
    Shen, Xue
    Cai, Tian
    Zhang, Dong-Mei
    Dong, Jian-Jun
    Liao, Lin
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 12481 - 12491